Published in Vaccine Weekly, April 14th, 1997
Previously, it was shown that HIV-1 acts as a superantigen for normal B lymphocytes, inducing abnormally widespread activation by crosslinking membrane IgM.
"This superantigen-like property is thought to be responsible for the increase in VH 3+ B cells during early stages of the infection followed by their progressive decline during advanced stages of the disease," noted Saoussen Karray and Moncef Zouali of the Pasteur Institute, Paris France.
In a paper published in the Proceedings of the National Academy of Sciences, Karray and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly